

## I. AMENDMENTS

### IN THE CLAIMS

Cancel claims 28-32 and 34 without prejudice to renewal.

Please enter the amendments to claims 33 and 35, as shown below.

1.-22. (Canceled)

23. (Previously presented) A method of treating a condition amenable to treatment by promoting angiogenesis, the method comprising:

administering recombinant human relaxin (H2) to a patient at a predetermined rate so as to maintain a serum concentration of at least about 1 ng/ml;

continuing the administration over a period sufficient to promote angiogenesis and treat the condition, wherein the condition is selected from the group consisting of an infection, and an ischemic wound.

24. (Previously presented) The method of claim 23, wherein relaxin is administered from an osmotic pump.

25. (Previously presented) The method of claim 24, wherein the osmotic pump is a multi-chamber osmotic pump system.

26. (Previously presented) The method of claim 23, wherein the predetermined rate comprises sequentially timed dispensing from an osmotic pump.

27. (Previously presented) The method of claim 23, wherein the administering is at a progressively diminishing rate.

28.-32. (Canceled)

33. (Currently Amended) ~~The method of claim 32;~~ A method of inducing secretion of vascular endothelial growth factor (VEGF) in a patient, comprising the steps of:  
administering recombinant human relaxin (H2) to the patient, wherein the administering induces VEGF secretion, and wherein the osmotic pump relaxin is administered at a predetermined rate  
a multi-chamber osmotic pump system, so as to maintain a serum concentration of at least about 1 ng/ml of relaxin for at least 72 hours in the patient.

34. (Canceled)

35. (Currently Amended) ~~The method of claim 28;~~ A method of inducing secretion of vascular endothelial growth factor (VEGF), comprising the steps of:  
administering recombinant human relaxin (H2) to a patient wherein the administering is in a sufficient amount and over a sufficient period of time so as to induce VEGF secretion, wherein the administering is at a progressively diminishing rate.